Cargando…

Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis

OBJECTIVE: To make a systematic evaluation of the clinical efficacy of thymopentin combined with antituberculous drugs in treating drug-resistant pulmonary TB (PTB). METHODS: Relevant studies were retrieved from PubMed, Embase, Cochrane Library, Chinese Biomedical Literature Database, CNKI, and Wanf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yi-Ran, Wang, Tian-Hao, Gong, Wen-Ping, Liang, Jian-Qin, An, Hui-Ru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977793/ https://www.ncbi.nlm.nih.gov/pubmed/35386182 http://dx.doi.org/10.2147/TCRM.S351317

Ejemplares similares

Mycobacterium tuberculosis resistance to antituberculosis drugs in Mozambique,
por: Pires, Germano Manuel, et al.
Publicado: (2014)

T cell development in normal and thymopentin-treated nude mice
Publicado: (1982)

Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
por: Farazi, Aliasghar, et al.
Publicado: (2014)

Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
por: Loukman, Moreea, et al.
Publicado: (2023)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Pattern of drug resistance of Mycobacterium tuberculosis clinical isolates to first-line antituberculosis drugs in pulmonary cases
por: Kalo, Deepika, et al.
Publicado: (2015)

Acquired Resistance to Antituberculosis Drugs
por: Aung, Htin Lin, et al.
Publicado: (2018)

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Antituberculosis drug-induced hepatotoxicity in children
por: Donald, Peter R
Publicado: (2011)

Diagnosis of Hypersensitivity Induced by Antituberculosis Drugs
por: Wu, Yuqing, et al.
Publicado: (2021)

Combination Effect of Antituberculosis Drugs and Ethanolic Extract of Selected Medicinal Plants against Multi-Drug Resistant Mycobacterium tuberculosis Isolates
por: Fauziyah, Prabasiwi Nur, et al.
Publicado: (2017)

Pharmacokinetics of antituberculosis drugs in critically ill patients with tuberculosis and acute respiratory failure
por: Hernandez-Cardenas, CH, et al.
Publicado: (2014)

Mycobacterium tuberculosisβ-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs
por: Aspatwar, Ashok, et al.
Publicado: (2019)

Molecular Analysis of Thymopentin Binding to HLA-DR Molecules
por: Liu, Zuojia, et al.
Publicado: (2007)

The Protective Effects of Water-Soluble Alginic Acid on the N-Terminal of Thymopentin
por: Ji, Haiyu, et al.
Publicado: (2023)

Microencapsulated Isoniazid-Loaded Metal–Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs
por: Fernández-Paz, Cristina, et al.
Publicado: (2021)

Treating More with Less: Effectiveness and Event Outcomes of Antituberculosis Fixed-dose Combination Drug versus Separate-drug Formulation (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide) for Pulmonary Tuberculosis Patients in Real-world Clinical Practice
por: Lai, Jacqueline Mui Lan, et al.
Publicado: (2019)

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism
por: Sistanizad, Mohammad, et al.
Publicado: (2011)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Drug-resistant tuberculosis in subjects included in the Second National Survey on Antituberculosis Drug Resistance in Porto Alegre, Brazil,
por: Micheletti, Vania Celina Dezoti, et al.
Publicado: (2014)

Pharmacokinetics of Antituberculosis Drugs in Plasma and Cerebrospinal Fluid in a Patient with Pre-Extensive Drug Resistant Tuberculosis Meningitis
por: Liang, Zhilin, et al.
Publicado: (2023)

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
por: Vaghela, Jitendra H., et al.
Publicado: (2018)

Preparation and Evaluation of Poly-Butylcyanoacrylate Nanoparticles for Oral Delivery of Thymopentin
por: He, Weiling, et al.
Publicado: (2008)

Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity
por: Wang, Yu, et al.
Publicado: (2019)

Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen
por: Heemskerk, A Dorothee, et al.
Publicado: (2017)

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai
por: Chen, Yong, et al.
Publicado: (2016)

Risk factors associated with adverse reactions to antituberculosis drugs
por: Resende, Laíse Soares Oliveira, et al.
Publicado: (2015)

Seizures following Intoxication with a Common Antituberculosis Drug
por: Lahlou, Adnane, et al.
Publicado: (2019)

Aureolic Acid Group of Agents as Potential Antituberculosis Drugs
por: Bespyatykh, Julia, et al.
Publicado: (2020)

Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
por: Ernest, Jacqueline P., et al.
Publicado: (2023)

Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis
por: Gallardo, Carmen R, et al.
Publicado: (2016)

In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients
por: Ying, Ruoyan, et al.
Publicado: (2021)

Thymopentin improves cardiac function in older patients with chronic heart failure
por: Xiaojing, Cao, et al.
Publicado: (2017)

Synthetic modifications of the immunomodulating peptide thymopentin to confer anti-mycobacterial activity
por: Wang, Ying, et al.
Publicado: (2014)

Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory?
por: Bigdon, Eileen, et al.
Publicado: (2022)

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
por: Gualano, Gina, et al.
Publicado: (2016)

Adverse drug reaction profile of daily regimen antituberculosis treatment
por: Sankar, K. N. Hari, et al.
Publicado: (2022)

Clinical impact of plasma concentrations of first-line antituberculosis drugs
por: Perumal, R, et al.
Publicado: (2023)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity
por: Zhang, Jingwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k6agih4jgisebg1q1d0u15e0fl